Largest market share for diabetes treatment in Brazil by end of 2025?
Novo Nordisk • 25%
EMS • 25%
Sanofi • 25%
Other • 25%
Market research reports and sales data published by industry analysts
Anvisa Approves EMS Production of Liraglutide Medications Lirux and Olire, First Competitor to Ozempic, for Sale in 2025
Dec 24, 2024, 02:11 PM
The Brazilian Health Regulatory Agency (Anvisa) has approved the production of two liraglutide-based medications by the pharmaceutical company EMS. The drugs, named Lirux and Olire, are intended for the treatment of type 2 diabetes and obesity, respectively. This marks the introduction of the first national competitor to Ozempic, a medication widely used for similar purposes. The approval was officially published in the Diário Oficial on December 23, 2024, and the medications are expected to be available for commercial sale in 2025. In a separate development, Anvisa has prohibited a supplement that falsely claimed to cure diabetes, which had been linked to misleading information about the disease.
View original story
Increase • 25%
Other • 25%
Decrease • 25%
Remain the same • 25%
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
Ozempic • 25%
Wegovy • 25%
Other • 25%
Mounjaro • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Eli Lilly 40-60% • 25%
Eli Lilly > 60% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Less than 30% • 25%
Yes • 50%
No • 50%
Other • 25%
AstraZeneca • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Decrease • 25%
No change • 25%
Slightly increase • 25%
Significantly increase • 25%
More than 75% • 25%
25% to 50% • 25%
Less than 25% • 25%
50% to 75% • 25%
Top 20 • 25%
Top 5 • 25%
Top 10 • 25%
Below Top 20 • 25%
Another competitor • 34%
Eli Lilly • 33%
Novo Nordisk • 33%
No significant change • 25%
Increase by 5-10% • 25%
Increase by over 10% • 25%
Increase by less than 5% • 25%
Ozempic • 25%
Other • 25%
Olire • 25%
Lirux • 25%